Amgen (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
$348.43
-$0.21(-0.08%)
At close: 4:00 PM EST
$348.43
-$0.21(-0.08%)
Day’s Range― - ―
52-Week Range$261.43 - $391.29
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.67M
Market Cap
$187.83B
Enterprise Value$233.30B
Total Cash (Recent Filing)$9.13B
Total Debt (Recent Filing)$54.60B
Price to Earnings (P/E)22.8
Beta0.43
Next Earnings
Apr 29, 2026EPS Estimate
4.78Next Dividend Ex-DateN/A
Dividend Yield3%
Share Statistics
EPS (TTM)5.29
Shares Outstanding539,067,700
10 Day Avg. Volume2,906,839
30 Day Avg. Volume2,668,111
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue6.35
Enterprise Value/Gross Profit9.00
Enterprise Value/Ebitda12.48
Forecast
1Y Price Target
$366.70Price Target Upside5.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering24
EPS Forecast (FY)22.41
Revenue Forecast (FY)$37.84B
Bulls Say, Bears Say
Bulls Say
Commercial MomentumAnalyst's Outperform view is supported by broad commercial strength across multiple marketed products, with recent earnings beats driven by strong sales of core brands that helped offset pricing pressures.
Rare Disease Franchise PositioningUplizna's twice-yearly dosing and distinct mechanism targeting CD19 B cells support adoption in rare disease indications such as IgG4-related disease and generalized myasthenia gravis, offering incremental franchise upside.
Repatha Access And Durable DemandRepatha benefits from broad formulary access and labeling for both primary and secondary cardiovascular prevention, and durable volume growth underpins continued revenue contribution.
Bears Say
Loss Of Exclusivity And Product ErosionProjected erosion of denosumab revenues and loss of exclusivity for key drugs represent a material headwind that will require meaningful offset from new launches or pipeline successes.
Obesity Program Tolerability And CompetitionUncertainty about MariTide's efficacy and tolerability, including nausea and vomiting concerns, combined with strong competition in the weight-loss therapy market, could limit its commercial uptake.
Pipeline And Regulatory SetbacksLate-stage program reorganizations, the termination of a co-development for a tolerability-limited asset, and regulatory requests tied to an existing medicine increase uncertainty around near-term pipeline contributions.
Amgen News
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $261.43 and its highest was $391.29 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $187.83B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Apr 29, 2026 which is in 35 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 03, 2026. The company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.734 by $0.556.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 4.78.
How many shares outstanding does Amgen have?
Amgen has 539,067,700 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $5.29 in its last earnings report, beating expectations of $4.734. Following the earnings report the stock price went up 8.154%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$366.70 (5.24% Upside)
$366.70 (5.24% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 92%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 653.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.30%
12-Months-Change
Fundamentals
Return on Equity
96.65%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Company Deck
AMGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized broad, multi-product commercial momentum, strong financial performance, substantial R&D investment, and encouraging late-stage pipeline progress (notably Repatha, Meritide, biosimilars, rare disease approvals, and Imdeltra). Key challenges include a significant regulatory action on Tavneos, slower-than-expected event accrual for the olpasiran outcome study, several program deprioritizations, and anticipated near-term sales pressure from biosimilars/generics and seasonal/inventory headwinds. On balance, the positives — sustained growth across multiple franchises, clear 2026 guidance range, and a deep late-stage pipeline — outweigh the notable but addressable setbacks.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$366.70
▲(5.24% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
24.43% Mutual Funds
21.30% Other Institutional Investors
24.11% Public Companies and Individual Investors